Hero image
EMPOWERING PATIENTS THROUGH

KINOME
INNOVATION

To be a champion for underserved conditions takes great ideas and great passion. Welcome to Aclaris, a biopharmaceutical company that strives to translate scientific discovery into everyday victories in immuno-inflammatory conditions.

Find out more »

Recent updates

Sep 17, 2024
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Sep 10, 2024
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Aug 07, 2024
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

We have the people, resources, and expertise to tackle some of the ‘white spaces’ in immuno-inflammatory conditions where significant gaps exist. 

Dr. Neal Walker
Co-founder and Chair of the Board of Directors
View our pipeline »